Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493178 · ClinicalTrials.gov registry record · Early Phase 1
Glutathione in Mild Cognitive Impairment
A Early Phase 1 study of Mild Cognitive Impairment, sponsored by Baylor College of Medicine.
- Active
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03493178 is a Early Phase 1 study of Mild Cognitive Impairment that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 60 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03493178, a Early Phase 1 study of Mild Cognitive Impairment, is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanisms linked to GSH for cognitive impairment (and improvement) by studying humans with mild cognitive impairment who will be evaluated 12-weeks after receiving either N-acetylcysteine and glycine (GSH precursors), or receiving alanine, and a further 12-weeks after stopping these supplements.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Glycine
- DIETARY_SUPPLEMENT Alanine
- DIETARY_SUPPLEMENT N-acetylcysteine (NAC)
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03493178
The ClinicalTrials.gov registry entry for NCT03493178 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 3 interventions - of which Glycine is the first listed.
NCT03493178 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03493178 about?
NCT03493178 is a clinical study titled "Glutathione in Mild Cognitive Impairment". Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanisms linked to GSH for cognitive impairment (and impr...
What is the current status of trial NCT03493178?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2018-04-19. Estimated completion is 2025-12-31.
What conditions does trial NCT03493178 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT03493178?
The interventions under investigation include: Glycine (DIETARY_SUPPLEMENT), Alanine (DIETARY_SUPPLEMENT), N-acetylcysteine (NAC) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03493178?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03493178 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
RECRUITING · Early Phase 1
-
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
ACTIVE NOT RECRUITING · Early Phase 1
-
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.